GT Medical Technologies, announced that it has raised $37 million in Series D financing round. The financing round was led ...

President Trump’s first term was bad,” he said, “but nobody knows what’s coming. … This is truly nationalism at its worst, because he won on the campaign [largely] to protect American jobs, claiming ...

Digital health firms in the city raised $4 billion in 2024, up 60% from the previous year, according to a report released ...

Cystic fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...

EVA Pharma of Africa, DNA Script and Quantoom Biosciences have signed a MoU to establish the mRNA production platform in Egypt.

BofA Securities, Goldman Sachs & Co. LLC, Evercore ISI, Guggenheim Securities and Cantor acted as joint bookrunners for the offering.

The Company granted options to purchase 250,000 shares of Terns common stock to the new employee. The options have a 10-year term and an exercise price per share equal to $4.46, which was the closing ...

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

Cystic fibrosis drug developer Sionna Therapeutics hopes to join the IPO wave started by Metsera and Maze Therapeutics last ...

Amongst the flurry of corporate earnings and economy-shaking announcements from the newly elected U.S. administration, the U.S. IPO pipeline maintains its steady pace. This week, building materials ...

Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into ...